TrialAIDS and behavior2025

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.

Cristina Mussini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.